Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Janssen
Woman and Man Max 99 years
Janssen Vaccines & Prevention B.V
Update Il y a 4 ans
A Clinical Safety Study of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Etude portant sur la tolérance clinique de sujets ayant été exposés aux vaccins candidats contre le virus Ebola Ad26.ZEBOV et/ou MVA-mBN226B
• To collect serious adverse event information from subjects exposed to Ad26.ZEBOV and/or MVA-BN-Filo in a Phase 1, 2, or 3 clinical study, for a total of 60 months after prime vaccination (including ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen Infectious Diseases BVBA
Update Il y a 4 ans
Safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen in MDR-TB (Multi-drug Resistant Tuberculosis)
− To evaluate safety, tolerability, and efficacy of TMC207 as part of a multi-drug regimen in the treatment of subjects with MDR-TB; − To evaluate the pharmacokinetics of TMC207 and its primary metab...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination therapy containing DRV/r in HIV-1 infected subjects with undetectable plasma HIV-1 RNA on their current treatments
To demonstrate non-inferiority in efficacy of DRV/r versus the triple combination therapy containing DRV/r, with respect to confirmed virologic response, defined as plasma HIV-1 RNA < 50 copies/mL at ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Jeroen Janssen, MD, PhD
Update Il y a 4 ans
Nilotinib Plus Pegylated Interferon-α2b in CML
The purpose of this trial is to assess the effect of switching CML patients, who have been treated with imatinib ≥ 2 years and who have stable detectable molecular residual disease between...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
Community Influenza
The primary objectives of the study is to evaluate the antiviral effect, as measured by viral titer in nasal secretions in adults with acute uncomplicated seasonal influenza A following administration...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Janssen Cilag International
Update Il y a 6 ans
Etude 63935937MDS3001 : étude de phase 3 visant à évaluer l’efficacité et la sécurité d’emploi de l’imételstat dans une 1ère partie, et son efficacité comparée à un placebo dans une 2ème partie chez des patients ayant un syndrome myélodysplasique (SMD), de risque IPSS faible ou intermédiaire-1 en rechute ou réfractaire à un traitement par agent stimulant de l’érythropoïèse (ASE).
Les syndromes myélodysplasiques (SMD) forment un ensemble de maladies caractérisées par la production insuffisante de cellules sanguines matures saines par la moelle osseuse. Les cellules sanguines im...
Country
France
organs
Syndromes myélodysplasiques (SMD)
Specialty
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Janssen R&D Ireland
Update Il y a 4 ans
TMC435HPC3002 - 3-Year Follow up of Patients After Administration of TMC435 for the Treatment of Chronic Hepatitis C
- To evaluate the durability of sustained virologic response (SVR) in subjects who were treated with a TMC435- containing regimen in a previous Phase IIb or Phase III study and maintained undetectable...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Janssen
Update Il y a 6 ans
Étude COLUMBA : étude de phase 3 randomisée comparant l’efficacité du daratumumab administré par voie intraveineuse à celle du daratumumab co-formulé avec la hyaluronidase humaine recombinante PH20 par voie sous cutanée chez des patients ayant un myélome multiple.
Le myélome multiple est une maladie de la moelle osseuse caractérisée par la multiplication dans la moelle osseuse d’un plasmocyte anormal. Le rôle des plasmocytes est de produire les anticorps (immun...
Country
France
organs
Myélomes
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
The primary objective is to evaluate if the addition of ibrutinib to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) prolongs event-free survival (EFS) compared with R-C...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
The purpose of this study is to estimate the proportion of participants fulfilling criteria for symptomatic remission following a transition to 12 months treatment with flexible-dose paliperidone palm...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next